Skip to main content
. 2015 Jun 16;9:218. doi: 10.3389/fnins.2015.00218

Figure 5.

Figure 5

Evaluation of specific MRP1 inhibition using siRNA and the effect of MRP1 knockdown on chemotherapy-induced cell death. Glioblastoma cell lines; U251, MZ-18, and MZ-256, representing commercial, primary tumor derived and recurrent tumor derived glioblastoma cell lines were transiently transfected with MRP1siRNA. MRP1 protein (190 kDa band) was reduced in all three cell lines 96 h post-transfection (A). Lane 1: Negative control siRNA-treated U251, Lane 2: MRP1siRNA-treated U251, Lane 3: Negative control siRNA-treated MZ-18, Lane 4: MRP1 siRNA-treated MZ-18 after 72 h, Lane 5: MRP1 siRNA-treated MZ-18 after 96 h, Lane 6: MRP1 siRNA-treated MZ-18 after 120 h, Lane 7: Negative control siRNA-treated MZ-256, Lane 8: MRP1 siRNA-treated MZ-256 after 96 h. The effect of specific MRP1 inhibition, using siRNA, was evaluated for temozolomide (150 μM), vincristine (100 nM), or etoposide (2 μM)– induced cell death and a significant increase in vincristine and etoposide-induced cell death in all three cell lines assessed; commercial (B), primary (C), and recurrent (D)-tumor derived representatives (n = 3 *p < 0.05, ***p < 0.001 Unpaired Student T-test) relative to single chemotherapy-induced cell death was noted.